Ultragenyx Pharmaceutical Inc. (0LIF.L)
| Previous close | 41.32 |
| Open | 40.97 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 40.61 - 40.97 |
| 52-week range | 31.83 - 54.48 |
| Volume | |
| Avg. volume | 302 |
| Market cap | 23.653M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.87 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireUltragenyx to Participate at Bank of America’s 2024 Healthcare Conference
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America’s 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT. The live and archived webcast
Insider MonkeyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72. RARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
Simply Wall St.Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) just released its latest first-quarter report and things are not looking...
